Dataset Information

Transcriptomic profiling of ventricular tissue from male C57BL/6J mice fed a high-fat/high-carbohydrate diet and treated with pirfenidone

ABSTRACT: This study evaluates cardiac ventricular gene expression changes associated with a high-fat/high-carbohydrate (HFHC) diet and pirfenidone treatment in male C57BL/6J mice. Dual-channel IFC UNAM Mouse 22 K v1 microarrays (GEO platform GPL34822) were used to compare pooled RNA samples from normal diet (ND), HFHC, and HFHC plus pirfenidone (HFHC+PFD) groups.

ORGANISM(S): Mus musculus

PROVIDER: GSE337556 | GEO | 2026/08/26

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Heart failure with preserved ejection fraction (HFpEF) is a life-threatening condition that affects more than half of all heart failure patients. Sodium-glucose cotransporter-2 inhibitor (SGLT2i) showed promising improvements in cardiovascular death or heart failure among HFpEF patients. This study aimed to test if cotreatment of Empagliflozin and Pirfenidone can improve the therapeutic outcome HFpEF by addressing the underlying cardiac fibrosis. We induced HFpEF in Sprague-Dawley rats using N-nitro-L-arginine methyl ester and a high-fat diet for 5 weeks, then treated them with EMPA, PFD, or both (EMPA+PFD) for 4 weeks. Echocardiography showed that EMPA+PFD significantly improved left ventricular ejection fraction (LVEF, p<0.0001), fractional shortening (FS, p=0.0427), stroke volume (SV, p=0.0019), and cardiac output (CO, p=0.0016) compared to the untreated group. These improvements were superior to PFD treatment alone (LVEF, p = 0.0131; CO, p = 0.040) and were absent in the EMPA group. Also, the late diastolic transmitral flow velocity and isovolumic relaxation time were much better with EMPA+PFD (p<0.0001) than with EMPA or PFD alone. PFD alone greatly reduced cardiac fibrosis in the subendocardial region. However, when EMPA and PFD were combined, the amount of fibrosis was significantly reduced in both the subendocardium (p<0.0001) and myocardium (p=0.0140). Myocyte cross-sectional area was significantly lower in both PFD-treated and EMPA+PFD-treated groups (p<0.001). However, only the EMPA+PFD group showed a significant reduction in left ventricular weight index (p = 0.0008), while the EMPA-treated group did not show these effects. Greater exercise capacity in HFpEF rats after EMPA+PFD treatment reflected the improvement in cardiac function, outperforming both EMPA and PBS-treated control. In conclusion, cotreatment with PFD and EMPA improves cardiac functions and reverses hypertrophic remodeling, suggesting a better strategy for treating HFpEF. Further investigation to decipher the cellular changes in ventricular CM may provide insights into the mechanism underlying the benefit of treatment combinations.

Dataset Information

Transcriptomic profiling of ventricular tissue from male C57BL/6J mice fed a high-fat/high-carbohydrate diet and treated with pirfenidone

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets